Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pulmonary Disease, Chronic Obstructive 1Pneumonia 1Lung Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Specimen Handling 17Radiotherapy 17Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11Fluorodeoxyglucose F18 10fludarabine 9X-Rays 9Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4olaparib 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × CIMAvax EGF × 1 year × Clear all
NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
2 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡